{"id":53214,"date":"2026-11-17T05:18:00","date_gmt":"2026-11-17T04:18:00","guid":{"rendered":"https:\/\/theark.ch\/?p=53214"},"modified":"2026-11-13T16:18:33","modified_gmt":"2026-11-13T15:18:33","slug":"ibex-therapeutics-secures-chf-640000-from-innosuisse","status":"publish","type":"post","link":"https:\/\/theark.ch\/en\/news\/ibex-therapeutics-secures-chf-640000-from-innosuisse\/","title":{"rendered":"ibex therapeutics secures chf 640,000 from innosuisse"},"content":{"rendered":"\n<h5 class=\"wp-block-heading\"><strong>based at the <a href=\"https:\/\/phytoark.ch\/en\/\" target=\"_blank\" rel=\"noreferrer noopener\">phytoark<\/a> technology site, start-up <a href=\"https:\/\/ibextx.ch\/en\/\" target=\"_blank\" rel=\"noreferrer noopener\">ibex therapeutics<\/a> has reached a new milestone in the development of its innovative plant-based therapy for oral mucositis, a common complication of cancer treatments. thanks to chf 640,000 in funding from innosuisse, the company is continuing the validation of its treatment in partnership with geneva university hospitals (hug) and the university of applied sciences and arts of western switzerland (hes-so valais-wallis).<\/strong><\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">ibex therapeutics, a swiss biotechnology company specialising in plant-based supportive therapies for oncology and oral diseases, has been awarded a grant of chf 640,000 by innosuisse. this funding will allow for the continued preclinical and clinical validation of its topical treatment for oral mucositis.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">oral mucositis, a painful ulcerative inflammation of the lining of the mouth, is one of the most frequent and debilitating side effects of cancer therapies. it affects approximately 33,000 oncology patients in switzerland and more than 780,000 in europe each year. in the absence of an effective standard of treatment, it hinders nutrition and may lead clinicians to interrupt cancer care.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">the treatment being developed by ibex therapeutics combines a proprietary extract of small-flowered willowherb (<em>epilobium lanceolatum<\/em>), a plant from the swiss alps rich in oenothein b, with <em>aloe barbadensis<\/em>. this combination is being studied for its anti-inflammatory, antioxidant, tissue-healing, bactericidal and antifungal properties.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>two scientific partnerships to accelerate innovation<\/strong><\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">innosuisse&#8217;s support funds two strategic areas, the results of which could lead to the filing of a new patent:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>clinical development (hug partnership):<\/strong> generate clinical evidence of safety and efficacy in patients undergoing oncological treatment (monitoring the evolution of mucositis during radiotherapy in patients with head and neck cancer).<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>preclinical research (hes-so valais-wallis partnership):<\/strong> demonstrate the anti-inflammatory, bactericidal and antifungal synergy of the ingredients to restore the oral microbiome.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cthis funding from innosuisse marks a turning point for ibex therapeutics and it validates our approach after a highly rigorous and competitive evaluation. it gives us the means to accelerate our development to generate new preclinical and clinical data expected by investors and bring our therapy to patients.\u201d &#8211; pierre morgon, ceo and co-founder of ibex therapeutics<\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>next step: securing further funding<\/strong><\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">ibex therapeutics is currently looking for an additional chf 800,000 over the next two years to pursue the development of this innovative product before signing an agreement with a strategic partner for worldwide distribution.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>about ibex therapeutics<\/strong><\/h5>\n\n\n\n<p class=\"wp-block-paragraph\">founded in 2021, ibex therapeutics sa develops innovative therapies based on plant extracts and probiotic portfolios. the company collaborates with partners specialising in development and production, as well as with academic institutions recognised for their scientific expertise.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>source: ibex therapeutics press release<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p> start-up ibex therapeutics has reached a new milestone in the development of its innovative plant-based therapy for oral mucositis, a common complication of cancer treatments.<\/p>\n","protected":false},"author":3,"featured_media":53197,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[211,230],"tags":[],"class_list":["post-53214","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health-and-sport","category-natural-ingredient"],"acf":[],"_links":{"self":[{"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/posts\/53214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/comments?post=53214"}],"version-history":[{"count":3,"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/posts\/53214\/revisions"}],"predecessor-version":[{"id":53218,"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/posts\/53214\/revisions\/53218"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/media\/53197"}],"wp:attachment":[{"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/media?parent=53214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/categories?post=53214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/tags?post=53214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}